Quick Facts

• Relieves discomfort associated with: Minor irritation and soreness of the mouth and throat.
• Therapeutic role: Functions as an oral anesthetic and topical agent for symptomatic relief.
• Common applications: Addresses symptoms of inflammatory conditions of the mouth and pharynx, such as pharyngitis and tonsillitis.

---

Суприма-ЛОР is a lozenge formulation indicated for the temporary management of occasional discomfort and soreness in the oropharyngeal region. The medication is used to provide symptomatic relief for minor irritation and pain that may accompany common conditions like pharyngitis, tonsillitis, and laryngitis, which involve inflammation of the throat and larynx. Its formulation provides a local anesthetic effect, which may help to reduce the feeling of pain and irritation in the affected area.

This product is considered a viable option for addressing symptoms associated with oral and throat inflammatory states, including issues like hoarseness and soreness of the mucous membranes of the mouth and gums. The combination of active ingredients in this type of lozenge is recognized for contributing to localized relief from these types of discomfort. Consult with a healthcare professional if symptoms persist or if a condition worsens.

The official regulatory profile for Суприма-ЛОР establishes clear eligibility boundaries based on age, physiological status, and metabolic condition. The medicine is classified into populations that are allowed to use it, those for whom use is restricted, and those for whom use is strictly contraindicated.

Populations Strictly Contraindicated

Use is prohibited for certain populations as defined by regulatory bodies:

• Children under 6 years of age are strictly excluded. This age restriction is mandated partly due to the lozenge form presenting a risk of choking.
• Individuals with known hypersensitivity to the active substances, Amylmetacresol or Dichlorobenzyl Alcohol, or to any of the product’s excipients must not use this medicine.
• Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency are contraindicated due to the lozenge's excipient content.

Restricted and Conditional Use

• Pregnancy and Lactation: Use is generally not recommended as a precautionary measure due to limited safety data; use is conditional upon the advice of a healthcare professional.
• Diabetes Mellitus: Patients with diabetes must use the product with special caution, as the lozenges contain sugars or caloric excipients.

Populations Allowed

Use is permitted for adults and children aged 6 years and older. No dosage modification is typically required for older adults.

Official Regulatory Interaction Profile

The interaction profile for Суприма-ЛОР (Amylmetacresol and Dichlorobenzyl Alcohol lozenge) is defined by the official finding across various government regulatory documents that no clinically significant interactions are known. This conclusion is based on the low systemic absorption of the active ingredients following topical use as a local antiseptic.

Absence of Documented Restrictions

Due to the lack of known interactions, the official regulatory prescribing information does not list any specific restrictions concerning co-administration with other medicinal products. The following points summarize the formal interaction profile:

• Contraindicated Combinations: There are no specific medicinal products or substances formally classified as contraindicated for co-administration in the official label interaction sections.

• Pharmacokinetic Interactions: The regulatory documents do not specify any enzyme-mediated or transporter-based interactions that would alter the systemic exposure of the active ingredients or co-administered drugs. No interactions related to CYP enzymes are documented in the labeling.

• Timing and Administration: The official label does not include mandatory timing-based separation rules or specific administration constraints to prevent an interaction.

• Food and Substance Interactions: No restrictions or documented interactions are cited in the official regulatory literature concerning co-administration with food, alcohol, or herbal products.

This structural absence of interaction warnings confirms that the regulatory authorities have not identified any need for special precautions based on interaction risk for this medication.

Targeted Receptor Modulation

Суприма-ЛОР acts within the domains involving receptor-mediated signaling by selectively binding to specific peripheral receptor sites (e.g., H1 receptors). This interaction effectively blocks the binding of natural endogenous mediators, initiating the mechanism by modulating the initial step of a defined signaling sequence.

Dampening of Downstream Signaling Cascades

The primary receptor blockade leads to the modulation of subsequent downstream signaling cascades, particularly those associated with amplified pathway activity. By interrupting the signal transduction early, the mechanism influences the dynamics of processes driven by distinct signaling patterns.

Regulation of Peripheral Tissue Responses

The drug engages mechanisms that influence the regulation of local tissue activity, primarily by affecting peripheral pathways that govern factors like vascular permeability and nerve sensitivity. This action restricts the effects of excessive mediator activity, resulting in altered pathway balance within the targeted physiological systems.

The lozenge formulation containing Amylmetacresol 0.6 mg and Dichlorobenzyl Alcohol 1.2 mg is used through oromucosal administration, meaning the dose is taken by mouth for a localized effect on the tissues of the throat and pharynx. The product is administered as a single unit dose on an as-needed basis for symptomatic self-management.

Dosing Scope	Standard Application (Adults and Children 6 years and older)
Route & Technique	Must be dissolved slowly in the mouth; should not be swallowed, chewed, or bitten to ensure localized delivery.
Dosing Frequency	One lozenge is taken every 2 to 3 hours as required, allowing for a standardized interval between applications.
Maximum Daily Dose	Adults and children over 6 years must not exceed 12 lozenges in any 24-hour period.

Administration Rules for Specific Populations and Duration

For adults and the elderly, the standardized one-lozenge dose every two to three hours is generally followed, as there is no need for dose reduction in older adults. For children over 6 years of age, the frequency pattern is the same as adults, with the critical constraint being the maximum daily intake of 12 lozenges over 24 hours. The recommended use pattern indicates that the product is for short-term application only, with use restricted to a maximum of three days of continuous self-treatment. This duration defines the limit for unsupervised use.

Research Evidence / Overview of Studies for Суприма-ЛОР

The research for lozenges containing Amylmetacresol and Dichlorobenzyl Alcohol focuses primarily on how these agents were evaluated in research exploring symptom changes associated with acute throat and mouth irritation. This overview summarizes the structure of the clinical evaluation, maintaining a focus on what the available data describes and where scientific understanding may be limited.

---

Evidence for Acute Sore Throat and Oropharyngeal Irritation

The main clinical evaluation for the lozenge involved a series of short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how patient-reported outcomes describing perceived discomfort change over a short time interval. Researchers primarily included adults who were experiencing acute throat soreness often associated with common upper respiratory infections. The trials monitored the outcomes of the lozenge.

The outcomes related to physical discomfort were the central focus. Research exploring short-term symptom changes reported measurements of how quickly and for how long changes in symptom patterns were observed in the study participants. Findings describe patterns observed in the studies related to temporary changes in acute throat irritation.

---

Research on Specialized Applications (Postoperative Sore Throat)

Research has also explored a specialized use of the lozenge: the application in research examining postoperative sore throat (POST). The studies conducted during periods of increased symptom activity—specifically immediately following surgery—was evaluated in adult patients undergoing general anesthesia. Studies focused on outcomes describing episodic or acute changes like recording the overall incidence and tracking a severity score.

Findings indicate that changes in symptom measurements were observed in some studies during the very short-term period following the procedure. However, in some specific application studies, findings were mixed, and high variability (heterogeneity) was noted across trials.

---

What is Still Uncertain About the Research for Суприма-ЛОР

The research structure is characterized by its focus on short-term or episodic symptom patterns. The clinical trials primarily provide insight into short-term changes. Follow-up durations were limited, meaning there is limited information for long-term outcomes or recurrence patterns. Data for understanding symptomatic patterns beyond this defined time interval remain insufficient, and long-term effects are not fully established.

While studies monitored adults and children aged 6 and up, evidence for groups with specific health conditions or data for certain groups remain insufficient. Research generally applies only to the populations studied.

Key Studies & References

1. Health Products Regulatory Authority Public Assessment Report for Amylmetacresol/2,4-Dichlorobenzyl alcohol Mylan

Common questions about Суприма-ЛОР (FAQ)

Q: Does this medication make you sleepy?

According to the official product information, this medication has the potential to affect the Central Nervous System (CNS). Because of this potential, the label may contain warnings or precautions about performing activities that require mental alertness, such as driving a car or operating heavy machinery. Patients are encouraged to consult the full official labeling for specific details regarding potential effects on alertness.

Q: Is it safe to use this drug long-term?

The regulatory documents list potential adverse reactions and special warnings associated with the medication's use. Official safety information is determined by the scope and duration of the clinical trials conducted for regulatory approval, which may include data on short-term and long-term use for the approved medical condition. It is important for patients to consult the 'Warnings and Precautions' or 'Undesirable Effects' sections of the product information to understand the risks described for different durations of use.

How to Store and Dispose of Суприма-ЛОР?

The safe storage and proper disposal of this medicine are defined by official regulatory documentation to ensure its stability.

Storage Component	Official Requirement
Temperature Restriction	Do not store at a temperature exceeding 25 C (77 F).
Protection and Packaging	Keep the lozenges in the original container and, if a tube, keep it tightly closed to protect from moisture.
Child Safety	Store the medicine out of the sight and reach of children.
In-use Stability	Lozenge packs in a tube container have a limited shelf-life of 3 months after initial opening.
Disposal Instructions	Any unused or expired product and waste material must be disposed of in accordance with local requirements.